reMYND and US Epilepsy Screening Program NINDS (ETSP) Begin Collaboration on Epilepsy Program


Press release

reMYND and the we ORNDS Epilepsy Therapeutic Screening Program (ETSP) to start collaborateto on the epilepsy program

Leuven Belgium, November 4 2021: reMYND NV, a clinical-stage company developing innovative treatments for Alzheimer’s disease, diabetes, epilepsy and other diseases caused by cellular dysfunction, today announces the acceptance of ReS3-T, the The Company’s leading epilepsy drug candidate in the United States NIH National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). The ReS3-T program is the result of a collaboration with the Center for Drug Design and Discovery (CD3) at KU Leuven.

The ETSP since its inception has focused on identifying promising new drug therapies for epilepsy and has made important contributions to the development of several FDA-approved drugs for epilepsy. The program offers screening for treatment compounds, with a focus on therapy-resistant epilepsies, disease prevention and modification, and performs tests with great scientific rigor.

ReS3-T acts via a novel, proprietary target, Pde6δ, to control neuronal activity and has shown strong evidence for its efficacy in several preclinical models of epilepsy, including Dravet syndrome. The newly identified neuroprotective compounds have demonstrated strong activity in restricting neuronal hyperexcitability in epilepsy, resulting in improved neuronal health and survival, including the ability to save cognition, confer neuroprotection, and potentially slow down epileptogenesis.

Epilepsy continues to affect far too many people around the world and, despite having done extensive research, treatments that effectively treat refractory epilepsies still have to be approved, ” said Gérard Griffioen, Chief Scientific OfficerIc Officer of reMYND. At reMYND, we has been researchis lying neuronal hyperexcitability for over a decade and our data have shown strong promise to fight disease in a fundamentally different and safe way.

Although a number of anti-epileptic drugs exist on the market, there remains a significant unmet need for treatments for drug-resistant epilepsies., “ noted Lode Debrabandère, Entrepreneur by reMYND. We are delighted to collaborate with the The Neurological Division of the NIH in the development of effective and safe treatment options potentially improve the quality of life of many patients living with epilepsy. “

Epilepsy affects approximately 50 million people worldwide. One third of patients do not respond to available medical treatments. Drug-resistant epilepsy is associated with significant morbidity, including decreased quality of life, increased injury and hospitalization rates, higher medical and psychiatric co-morbidities, high mortality rates, including increased sudden unexpected death in epilepsy and increased economic costs to society.

-ENDS-

About reMYND
reMYND is a clinical stage company developing new treatments for Alzheimer’s disease, diabetes, epilepsy and other diseases caused by cellular dysfunction. It is based on an exclusive drug discovery platform, which identifies new mechanisms of action, targets and first-in-class small molecules.

ReMYND’s most advanced program is ReS19-T, an investigational compound for the treatment of Alzheimer’s disease, which entered the clinic in the fourth quarter of 2020. In animal models, it has been shown to produce an acute response , restoring synaptic plasticity, a central process in the disease cascade leading to neuronal disappearance and the accumulation of plaques and tangles. The company is also developing a treatment for diabetes, ReS39. Animal models have demonstrated the efficacy of the compound in increasing the capacity of endogenous insulin production with a sustained and lasting effect on blood sugar levels and the protection of target organs.

Other treatments for major health problems are being explored using the reMYND discovery platform, with a focus on mitochondrial dysfunction in central nervous system (CNS) disorders.
In addition, reMYND has a dedicated Contract Research Organization (CRO), which focuses on CNS disorders. The team helps clients assess the pharmacokinetics, pharmacodynamics, and efficacy of their experimental treatments in reMYND’s proprietary animal models. The CRO has a global client base, including the United States, Europe and Japan.

reMYND was founded in 2002 as a spin-off from the University of Louvain and was substantially supported by grants from VLAIO / IWT (Flanders, Belgium). To learn more, visit https://www.remynd.com.

About Michael Bill

Check Also

Fundraiser honors young life lost and raises GFC scholarships

A party at the New York Eatery on May 15 celebrated the life of young …

Leave a Reply

Your email address will not be published.